1020 results about "In vivo experiment" patented technology

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.

The invention belongs to the field of biological medicines, and particularly relates to a modified double-stranded oligonucleotide, and a conjugate and a composition thereof. The double-stranded oligonucleotide provided by the invention effectively enhances the activity of the double-stranded oligonucleotide for inhibiting the expression of the target gene by performing specific modification on the nucleotide at a specific site, can efficiently inhibit the expression of the target gene in both in-vitro and in-vivo experiments, and surprisingly, the double-stranded oligonucleotide provided by the invention has a good application prospect. The modification on the double-stranded oligonucleotide can be generally used for siRNA designed for various different target genes, and the inhibition rate of the siRNA on the target genes can be effectively improved.

The invention provides an anticoagulant coating for medical instruments, which can be used in the field of regenerative medical instruments. The prepared anticoagulant coating has short-term and long-term anticoagulant performance, and in addition, the thrombin responsive nanoparticles wrapped in the hydrogel coating can selectively release a factor Xa (FXa) inhibitor apixaban according to needs, so that thrombosis is inhibited in the middle stage of implantation. In-vitro and in-vivo experimental evidences show that after the material is implanted for a long time, an organized endodermis can be seen on the surface of the material, and the material has a special antithrombotic characteristic. The dynamic adjusting system has a multi-layer protection mechanism, and a new thought can be provided for designing the surface of a contact blood material adapting to environmental conditions.

The invention discloses Klebsiella oxytoca G1-2-4 and application thereof, and particularly relates to application of the Klebsiella oxytoca G1-2-4 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.30986 in preparation of a biocontrol preparation or feed for preventing and treating aquatic diseases. The invention further discloses application of the Klebsiella oxytoca G1-2-4 in preparation of the biocontrol preparation or feed for preventing and treating the aquatic diseases and application of the Klebsiella oxytoca G1-2-4 in preparation of the biocontrol preparation or feed for preventing and treating the aquatic diseases. The invention relates to an application of klebsiella oxytoca G1-2-4 in inhibiting the growth of pseudomonas plecoglossicida and a biocontrol preparation or feed containing the klebsiella oxytoca G1-2-4 and used for preventing and treating aquatic diseases. According to the Klebsiella oxytoca cultured in an isolated mode, the disease resistance of the Klebsiella oxytoca is verified through in-vitro and in-vivo experiments, the disease resistance mechanism of the Klebsiella oxytoca is preliminarily explored, and reference is provided for research on prevention and treatment of the visceral white-spot disease of the small yellow croakers.

The invention relates to application of a tea exosome in preparation of a medicine for improving skin pigmentation, the tea exosome is creatively extracted and purified, and the tea exosome can effectively inhibit proliferation of melanoma cells and inhibit expression of melanin generation related protein by scavenging free radicals and inhibiting tyrosinase activity, so that the effect of improving skin pigmentation is achieved. The intracellular melanin removal is promoted. In a mouse in-vivo experiment, after the tea exosome is applied, it is observed that the skin epidermis thickness of a mouse is reduced, the dermis thickness is increased, collagen arrangement is tighter and more ordered, the content is increased, and meanwhile generation of inflammatory factors is reduced. The tea exosome can significantly increase the content of a melanin autophagy key factor LC3B and reduce the content of P62 to promote melanin autophagy, and has good percutaneous infiltration capacity, thereby playing a role in improving skin pigmentation.

The invention discloses a bioactive peptide with antioxidant and hypoglycemic functions, a composition and application, and belongs to the technical field of bioactive peptides. The amino acid sequence of the bioactive peptide with the antioxidant and hypoglycemic functions is as shown in one of SEQ ID NO: 1-SEQ ID NO: 4. According to the method, the degreased peanut meal is subjected to enzymolysis by combining multiple enzymes, so that the diversity of peptide fragments is improved, and a high-activity enzymolysis product is obtained through condition optimization. An enzymolysis product is separated and purified by utilizing an ultrafiltration and high performance liquid chromatography-mass spectrometry combined technology, so that the purity and the structural definition of the peptide fragment are ensured. The bioinformatics technology is combined for screening, so that the activity and effect of the peptide sequence are improved. In-vitro and in-vivo experiments prove that the separated bioactive peptide has good antioxidant and hypoglycemic effects, and has a wide application prospect in preparation of antioxidant and hypoglycemic products.

The invention belongs to the technical field of biological medicine, and discloses application of magnolol as a polymyxin synergist in inhibition of salmonella. The application finds that the combination of magnolol and polymyxin has a good synergistic effect on salmonella in vitro and in vivo experiments. Compared with the traditional method of killing salmonella through combination of antibiotics, the method has the advantages that the magnolol and the polymyxin which are plant-derived synergistically kill bacteria, the generation of bacterial drug resistance is not easy to induce, and the magnolol has the characteristics of wide source, low price and good treatment effect; the method has good research and application significance for excavating antibiotic synergistic substitution and solving bacterial drug resistance.

The invention belongs to the technical field of medicines, and particularly discloses application of niclosamide in preparation of a medicine for treating epididymis and testis fibrosis caused by bacterial infection. A UPEG-mouse epididymis / orchitis model is firstly constructed, a result shows that a monocyte subset highly expressed by S100a4 appears in a testis, the group of cells mainly express CD11b monocyte characteristics in the early stage when entering the testis, and the group of cells are partially converted into F4 / 80 + and alpha-SMA + fibroblast characteristics in the later stage. A myeloid macrophage knockout mouse is used for constructing a UPEG-epididymis / orchitis model, and the fibrosis degree of testis and epididymis is obviously reduced; a molecular mechanism shows that S100a4 can strengthen a TGF beta-STAT3 signal channel to promote the transformation of macrophages to fibroblasts, and niclosamide can inhibit the process. Mouse in-vivo experiment results show that niclosamide can obviously inhibit UPEG-mouse epididymis and testis fibrosis.

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention relates to the field of modified milk, in particular to pasteurized modified milk with a lead ion emission reduction function and application of the pasteurized modified milk. The pasteurized modified milk provided by the invention contains lactobacillus mucus fermentation B44, wherein the preservation number of the lactobacillus mucus fermentation B44 is CGMCC (China General Microbiological Culture Collection Center) No.17321. Compared with a control sample and other strains, the lactobacillus mucilaginosus B44 in the pasteurized modified milk provided by the invention can remarkably reduce the lead content in intestinal content supernatant, and results of in-vivo experiments of rats show that the lactobacillus mucilaginosus B44 can remarkably reduce the blood lead concentration, the lead content in livers and the lead content in kidneys of drinking objects, so that the lactobacillus mucilaginosus B44 can be used for preparing the pasteurized modified milk. The discharge of lead in excrement can be increased, and liver oxidative damage caused by lead poisoning can be effectively relieved, so that the method can be applied to research on in-vivo emission reduction of lead.

The invention discloses application of PABPC3 as a marker for evaluating prognosis of metastatic ovarian cancer, and belongs to the technical field of biological diagnosis and medicine. Specifically, differential genes in an in-situ ovarian cancer and a metastatic ovarian cancer in a database are screened, and are combined with differential genes related to ovarian cancer prognosis in a pan-cancer database, so that a gene PABPC3 with remarkable differential expression is obtained. The influence of the gene PABPC3 on the activity, migration ability and the like of ovarian cancer cells is researched through cell experiments and in-vivo experiments, and the feasibility of the marker in evaluation of ovarian cancer prognosis is proved. Meanwhile, the invention also discovers that the expression of the knock-down gene PABPC3 can inhibit the metastasis of cancer cells. Therefore, the invention provides a novel strategy for detecting and treating ovarian cancer metastasis, which is expected to overcome the defects of the traditional detection and treatment mode, and provides a new choice for clinic.

The invention provides a nanoparticle capable of releasing EGCG (epigallocatechin gallate) in response to ROS (reactive oxygen species) as well as a preparation method and application of the nanoparticle. The nanoparticles comprise a carrier and EGCG (epigallocatechin gallate) loaded on the carrier; the carrier is Prussian blue nanoparticles of which the surfaces are modified with polyethyleneimine and phenylboronic acid compounds. The preparation method of the nanoparticles is simple and easy to operate, the nanoparticles are good in dispersity, and through research, the nanoparticles have CAT-like, SOD-like and other multi-enzyme activities, can remove. OH, have a high EGCG drug loading rate and release EGCG in the presence of ROS. Besides, the nanoparticles show a good effect of improving myocardial ischemia reperfusion injury in cell level and rat in-vivo experiments, through comparison of EGCG and PB NPs single-drug treatment, synergistic treatment in the composite material achieves an effect of '1 + 1 > 2', and the composite material has good biological safety.

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

The invention provides a blood fat reducing polypeptide as well as a screening method and application thereof, and belongs to the field of polypeptides. The blood fat reducing polypeptide provided by the invention comprises at least one of 116 polypeptides with amino acid sequences of FFPFF, VFFFPF, PFFFF, AFFFPFF, LFFFPFY and the like. The blood fat reducing polypeptide provided by the invention can effectively reduce blood fat, has no obvious toxic or side effect, shows good inhibitory activity on steroid esterase and lipase in an in-vitro enzyme activity test, and also can effectively reduce blood fat in an animal in-vivo experiment; and no obvious toxic or side effect is shown in toxicity prediction and animal in-vivo models.

Provided is a long-acting kinin or a derivative thereof, for use in fundamentally solving the problem that the kinin is undruggable. On the one hand, the half-life period of the kinin or the derivative thereof is prolonged by means of long-acting technology, preventing the kinin or the derivative thereof from being rapidly degraded and inactivated in vivo; and on the other hand, action sites of the kinin and a receptor are covered or partially covered by means of long-acting modification, effectively avoiding rapid decrease of blood pressure in a short time, hypotension, and other adverse reactions. The long-acting kinin or the derivative thereof well retains receptor binding activity and signal conduction activity in an in-vitro cell experiment, and can effectively treat hypertension and prevent or treat hypertension complications in in-vivo experiments, and thus a novel method for treating hypertension and hypertension complications is provided.

The invention discloses an anti-tumor medicine composition combined with a PARG inhibitor and application. Through natural product library screening and CCK-8 experiments, it is found that PARG knockout gastric cancer cells show significantly enhanced sensitivity to ginsenoside CK. Further clone formation experimental analysis shows that PARG knockout significantly enhances the inhibitory effect of ginsenoside CK on gastric cancer cell proliferation. In in-vivo experiments, a CDX model is utilized to verify that PARG knockout can significantly enhance the anti-tumor activity of ginsenoside CK on gastric cancer. The discovery provides an important experimental basis for clinical application of PARG as a gastric cancer treatment target and ginsenoside CK as a potential treatment drug. The research finds that the PARG inhibitor and ginsenoside CK are combined to achieve a better killing effect on other various cancer cells, and it is indicated that improvement of the effect is broad-spectrum.

The invention provides an application of puerarin in treatment of periodontitis. The molecular mechanism of puerarin (Pue) for treating periodontitis (PDS) is verified through a plurality of in-vitro and in-vivo experimental studies. In PDS mice, Pue treatment relieves periapical tissue inflammation and bone destruction, and promotes osteogenic differentiation and autophagy of periapical tissues. In a PDS cell model, Pue treatment promotes osteogenic differentiation and mitochondrial autophagy, inhibits inflammation, maintains mitochondrial membrane potential and mitochondrial dynamic homeostasis, and activates mitochondrial Mfn2. In addition, the mitochondrial autophagy inhibitor eliminates the influence of Pue on a PDS cell model, and Mfn2 silence reverses mitochondrial autophagy enhancement induced by Pue. In-vivo tests verify that Mfn2 knockout counteracts the therapeutic effect of Pue on PDS mice. The invention provides a sufficient basis and an exact molecular mechanism for application of puerarin in treatment of periodontitis.

The invention provides a camellia nitidissima plant endophytic bacterium as well as a fungicide and application thereof in resisting influenza A virus. The golden camellia plant endophytic bacteria are bacillus thuringiensis and are preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.32945. A fermentation product of the strain shows good antiviral activity in both in-vitro and in-vivo experiments, and can effectively inhibit replication of influenza viruses and protect infected mice from being damaged by lethal influenza viruses; the compound also shows the effect of regulating immune response, and the secretion of IFN-gamma is enhanced by down-regulating the secretion of proinflammatory factors such as IL-6 and IL-10, so that the immune resistance of the body is improved.

The invention relates to application of an MYZAP overexpression recombinant vector in preparation of a medicine for preventing and treating arrhythmia, and belongs to the technical field of biological medicines. In order to solve the problem that application of gene drugs in prevention and treatment of arrhythmia after myocardial infarction is limited, the invention provides application of a myocardial microbelt adhesion protein MYZAP overexpression recombinant vector in preparation of drugs for prevention and treatment of arrhythmia, and the MYZAP overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP of an overexpression MYZAP gene. In-vivo experiments prove that MYZAP overexpression can reduce the occurrence of arrhythmia after myocardial infarction by increasing the content of MYZAP protein in cardiac myocardial cells, and improve cardiac functions and cardiac electrical conduction disorders after myocardial infarction. On the basis, the invention further provides a medicine for preventing and treating arrhythmia after myocardial infarction, a new strategy is provided for gene therapy of arrhythmia after myocardial infarction, and the medicine has a wide clinical application prospect.

The composition is of a network structure and is composed of strontium ions and chlorogenic acid, and the weight ratio of the strontium ions to the chlorogenic acid is 1: (9-11). The composition and hydrogel are mixed to prepare a microneedle patch, and the microneedle patch is prepared into a medical instrument for wound repair. Through verification, the SrC-MPNs is continuously released by the SrC-MPNs (at) MN-PP, so that the substances are dissolved and absorbed into tissue fluid around a wound, and strontium ions and chlorogenic acid in the SrC-MPN can stably and continuously exert the effects of resisting bacteria and oxidation, promoting angiogenesis, promoting wound healing and the like. An in-vivo experiment result shows that the SrC-MPNs (at) MN-PP can promote in-vivo and in-vitro wound healing, promote M2 macrophage polarization, remove excessive ROS and promote angiogenesis and tissue regeneration so as to promote healing of diabetic wounds.

The invention relates to the technical field of medicines, and provides a lanosterol derivative as well as a preparation method and application thereof. The lanosterol derivative provided by the invention has a structural formula as shown in a formula I or a formula II. The lanosterol derivative provided by the invention has both fat solubility and water solubility, and can effectively permeate into a diseased region in a body, so that the medicinal availability is improved; results of the embodiment show that the solubility of the lanosterol derivative provided by the invention in water is obviously higher than that of lanosterol or 25-hydroxylanosterol, and the lanosterol derivative shows an obvious cataract treatment effect in animal in-vivo experiments and has a wide prospect in preparation of drugs for treating eye diseases or symptoms. # imgabs0 #

The provided long-acting kinin or the derivative thereof fundamentally solves the problem that kinin has no druggability, on one hand, the half-life period of kinin or the derivative thereof is prolonged through a long-acting technology, and it is prevented that kinin or the derivative thereof is rapidly degraded and inactivated in vivo; on the other hand, the action site of the kinin and the receptor is covered or partially covered through long-acting modification, so that the adverse reactions such as rapid blood pressure reduction and hypotension in a short time are effectively avoided. The long-acting kinin or the derivative thereof well retains receptor binding activity and signal transduction activity in an in-vitro cell experiment, can effectively treat hypertension and prevent or treat hypertension complications in an in-vivo experiment, and provides a new method for treating hypertension and hypertension complications.

The invention provides a camptothecin prodrug. The camptothecin prodrug provided by the invention has higher drug retention in the liposome and better stability, and the prodrug liposome can maintain long-time plasma concentration in plasma. In-vitro characterization of the camptothecin prodrug liposome shows that the camptothecin prodrug liposome has higher encapsulation efficiency, drug loading capacity and stability, and can achieve a slow release effect in plasma; the experimental result on the cellular level shows that the compound has higher cellular uptake rate; in-vivo experiments prove that the compound has a better tumor accumulation effect and antitumor activity, can tolerate a higher dosage, and has higher biological safety.

The invention is applicable to the technical field of hydrogel, and provides dynamic cross-linked hydrogel and a preparation method and application thereof, and the preparation method comprises the following steps: cross-linking oxidized dextran and carboxymethyl chitosan containing phenylboronic acid modification groups; glucanase is added before the hydrogel is formed, and calcium peroxide nanoparticles coated with polydopamine are introduced; wherein the mass concentration of the oxidized dextran is 2-10% w / v, the mass concentration of the carboxymethyl chitosan containing the phenylboronic acid modified group is 2% w / v, the concentration of the glucanase is 10-100 U, and the concentration of the calcium peroxide nanoparticles coated with the polydopamine is 0.1-1% w / v. The hydrogel disclosed by the invention shows good cell compatibility, angiogenesis promoting capability and bioactivity for promoting dental pulp regeneration in multiple in-vitro and in-vivo experiments, is suitable for tissue engineering fields such as dental pulp injury repair and the like, and effectively solves the technical problem that conventional hydrogel is insufficient in cell survival support in three-dimensional culture and the like.

The invention discloses application of naringenin in preparation of a medicine for preventing and treating diseases caused by pseudorabies virus, and belongs to the technical field of biological medicine. The naringenin has good anti-PRV activity in vivo and in vitro. The naringenin can inhibit virus proliferation of the pseudorabies virus in an intracellular replication stage, reduce expression of PRV gB protein, lower expression of TLR4 and P65 protein to inhibit activation of an NF-kB pathway and lower expression of an inflammatory gene, and reduce nucleation of the NF-kB / P65 protein to achieve anti-inflammatory and antiviral effects. In-vivo experiments prove that naringenin can delay the disease time of mice, reduce the virus load in organs of the mice infected by PRV and relieve pathological changes of tissues and organs of the mice, and in addition, the survival rate of the mice infected by viruses is improved by adjusting the serum cell factor level of the mice. The naringenin provides a new strategy for preventing and treating PRV infection.

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention discloses application of an SUMO inhibitor 2-D08 in preparation of drugs for treating chronic myelogenous leukemia (CML) and drug resistance of a tyrosine kinase inhibitor (TKI) of the SUMO inhibitor 2-D08. It is revealed for the first time that SUMOylation modification drives disease progression by stabilizing BCR-ABL protein, 2-D08 promotes BCR-ABL protein degradation by inhibiting the modification, and leukemia cell proliferation is remarkably inhibited. In-vitro experiments prove that the compound effectively inhibits the activity of TKI drug-resistant cells, and in-vivo experiments show that 5 mg / kg of the compound can improve liver and spleen infiltration of CML mice. The inhibitor provides a new scheme for overcoming drug resistance, and fills the application blank of SUMOylation modification in CML treatment.

The invention relates to a polypeptide capable of promoting tuft cell proliferation and application of the polypeptide in treatment of inflammatory bowel diseases, in particular to a polypeptide Sjp40-73 derived from schistosome egg protein, and the amino acid sequence of the polypeptide Sjp40-73 is SEQ ID NO.1. The invention further relates to a preparation method of the polypeptide Sjp40-73. The polypeptide can be obtained through methods such as genetic engineering expression or chemical synthesis. In-vitro experiments prove that the peptide can effectively increase the number of tuft cells of intestinal organs of mice; in-vivo experiments further prove that the peptide can relieve mouse inflammatory bowel diseases and can improve corresponding inflammations. The polypeptide prepared by the invention can be applied to medicines, health-care products or food additives for preventing and treating inflammatory enteritis.

The present invention relates to the field of microbial fermentation technology, and in particular to a Pediococcus pentosaceus ZKPp0412, Pueraria lobata fermentation liquid and their application in preparing alcohol sobering and liver protecting products. Pediococcus pentosaceus )ZKPp0412 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on June 21, 2023, with the deposit number CGMCC No.27674, and the deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. The Pueraria lobata fermentation liquid prepared by fermenting the Pueraria lobata extract by this strain has a lower pH and a higher number of viable bacteria, and can promote the activity of alcohol dehydrogenase and acetaldehyde dehydrogenase in vitro. In vivo experiments have verified that the Pueraria lobata fermentation liquid has the effect of sobering up and sobering up drunk mice, and can effectively inhibit alcohol-induced liver enlargement / liver damage.

The invention discloses a Nur77 methylation site mutation peptide based on structural modification design and application of the Nur77 methylation site mutation peptide in promoting embryo implantation, according to the mutation peptide, arginine at the 346th site of Nur77 is mutated into lysine, and methylation modification of Nur77 is reserved while phosphorylation of Nur77 is inhibited, so that the transcriptional activity of Nur77 is enhanced. It is found that the mutant peptide can promote deciduation of endometrial interstitial cells, remarkably improve deciduation disorder of infertility mice in in-vivo experiments and improve the embryo planting rate of low-fertility mice. Therefore, the mutant peptide is expected to become a new medicine for treating the uterine-derived infertility and has important clinical application value. The invention also relates to a preparation method of the mutant peptide and application of the mutant peptide in a pharmaceutical composition and a treatment method.